TMS Co (TSE:4891) OCF Margin %: 0.00% (As of Dec. 2025)


TSE:4891 TMS Co Ltd TSE:4891
33 GF Score
Price 円101.00
! 1 Warning Sign
View Full Analysis

What is TMS Co OCF Margin %?

TMS Co TSE:4891 33 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4891 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, TMS Co ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. TMS Co's Cash Flow from Operations for the three months ended in Dec. 2025 was 円0.00 Mil. TMS Co's Revenue for the three months ended in Dec. 2025 was 円0.00 Mil. Therefore, TMS Co's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, TMS Co's current OCF Yield % is -10.32%.

The historical rank and industry rank for TMS Co's OCF Margin % or its related term are showing as below:


During the past 5 years, the highest OCF Margin % of TMS Co was 64.82%. The lowest was 64.82%. And the median was 64.82%.

TSE:4891's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

TMS Co OCF Margin % Related Terms

TMS Co OCF Margin % Historical Data

* Premium members only.

The historical data trend for TMS Co's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMS Co OCF Margin % Chart

TMS Co Annual Data
Trend Feb21 Feb22 Feb23 Feb24 Feb25
OCF Margin %
0.00 64.82 0.00 0.00 0.00

TMS Co Quarterly Data
Feb21 Feb22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Feb25 May25 Aug25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4891
33GF Score
TMS Co Ltd TSE:4891
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

TMS Co's OCF Margin for the fiscal year that ended in Feb. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Feb. 2025 )/Revenue (A: Feb. 2025 )
=-493.756/0
= %

TMS Co's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
TMS Co (TSE:4891) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on TMS Co and its competitors. Over the past decade, TMS Co's OCF Margin % has ranged from 64.82 to 64.82. According to the industry distribution chart, TMS Co ranks #999999 out of 959 companies in the Biotechnology industry.
Is TMS Co's OCF Margin % too high?
TMS Co's current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 64.82 to a high of 64.82. Based on the distribution chart, TMS Co ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TMS Co has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TMS Co ranks #999999 out of 959 companies for OCF Margin %. This places TMS Co in the lower half of its industry. Historically, TMS Co's own OCF Margin % has ranged from 64.82 to 64.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on TMS Co and its competitors. TMS Co's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. TMS Co's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For TMS Co (TSE:4891), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
33GF Score

Get the complete analysis for TSE:4891

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円101.00
Price